Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Shareholders are rewarding the kinds of companies they punished a year ago.
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
The pandemic provided the best and worst of times for smid-cap medtechs.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.